Document Classification

Section Type: METHODS

Text: Between 1989 and 1993, 710 pre - and perimenopausal women with axillary node-positive breast cancer were randomly assigned to either cyclophosphamide 75 mg/m (2) orally days 1 through 14, epirubicin 60 mg/m (2) intravenously days 1 and 8, and fluorouracil 500 mg/m (2) intravenously days 1 and 8 (CEF) or CMF (cyclophosphamide 100 mg/m (2) orally days 1 through 14, methotrexate 40 mg/m (2) intravenously days 1 and 8, and fluorouracil 600 mg/m (2) intravenously days 1 and 8).